[Evidence and utility of etidronate for the treatment of osteoporosis].

Abstract

Etidronate is the first bisphosphonate for the treatment of osteoporosis in Japan. Etidronate is useful for the treatment of postmenopausal osteoporosis, glucocorticoid induced osteoporosis, osteoporosis in men, and disused osteoporosis. Etidronate is less effective than other bisphosphonate, such as alendronate and risedronate, in reduction of fracture risk especially non-vertebral fracture, although bone mineral density in femoral neck is significantly increased.

• Authors: Junichi Takada, Kousuke Iba, Toshihiko Yamashita, Takashi Yoshizaki
• Journal: Clinical calcium (Clin Calcium) Vol. 18 Issue 10 Pg. 1427-33 (Oct 2008) ISSN: 0917-5857 [Print] Japan
• PMID: 18830039 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Bone Density Conservation Agents
• Etidronic Acid

Topics

• Bone Density
• Bone Density Conservation Agents (administration & dosage)
• Etidronic Acid (administration & dosage)
• Evidence-Based Medicine
• Female
• Femur Neck (metabolism)
• Humans
• Lumbar Vertebrae (metabolism)
• Male
• Meta-Analysis as Topic
• Osteoporosis (drug therapy, etiology, metabolism)
• Risk
• Spinal Fractures (etiology, prevention & control)